Autoimmune Uveitis Market to Expand at a CAGR of 7% During the Forecast Period (2026-2036) as Novel Treatments Challenge the Existing Therapeutic Landscape | DelveInsight
The autoimmune uveitis market is poised for steady growth, driven by the increasing recognition and diagnosis of non-infectious uveitis, the need for steroid-sparing therapies, and continued advances in targeted immunomodulatory treatments. Growth is expected to accelerate as emerging therapies such as Brepocitinib (Priovant Therapeutics), TRS01 (Tarsier Pharma), RAY121 (Chugai Pharmaceutical), and others seek to address unmet needs through novel mechanisms and potentially improve efficacy, durability, and safety.
LAS VEGAS, Sept. 2, 2026 /PRNewswire/ -- Recently published Autoimmune Uveitis Market Insights report includes a comprehensive understanding of current treatment practices, autoimmune uveitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Autoimmune Uveitis Market Summary
Discover autoimmune uveitis clinical trial 2026 update press release @ http://delveinsight.com/report-store/autoimmune-uveitis-market
Key Factors Driving the Growth of the Autoimmune Uveitis Market
Aparna Thakur, Project Manager of Forecasting & Analytics at DelveInsight, said that the conventional corticosteroids and immunosuppressive agents currently dominate the autoimmune uveitis treatment landscape; however, targeted biologics, JAK/TYK2 inhibitors, and advanced localized drug delivery systems are expected to drive future innovation by providing safer, more durable, and steroid-sparing treatment options.
Autoimmune Uveitis Market Analysis
Autoimmune Uveitis Competitive Landscape
Some of the autoimmune uveitis drugs under development include Brepocitinib (Priovant Therapeutics), TRS01 (Tarsier Pharma), RAY121 (Chugai Pharmaceutical), NOV05 (Novaliq), PST-606 (PulseSight Therapeutics), and others.
Tarsier Pharma's TRS01 is a polypeptide conjugate designed to exert a dual mechanism of action. The investigational therapy promotes the activation of anti-inflammatory macrophages while also suppressing nuclear factor-kB (NF-kB) signaling through toll-like receptor 4 (TLR4). TRS represents a proprietary, bio-inspired platform being developed for the treatment of blinding ocular diseases.
Priovant's lead investigational therapy, brepocitinib, is an oral, once-daily dual TYK2/JAK1 inhibitor. The drug is in late-stage development for multiple severe autoimmune diseases that have limited or no approved targeted treatment options and has demonstrated positive outcomes across several Phase II and Phase III studies. Priovant is also assessing brepocitinib in a Phase III trial for non-infectious uveitis (NIU), with topline results anticipated in the second half of 2026.
The anticipated launch of these emerging therapies are poised to transform the autoimmune uveitis market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the autoimmune uveitis market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
Discover more about the latest treatments for autoimmune uveitis 2026 @ Autoimmune Uveitis Therapeutics Clinical Trials
Recent Developments in the Autoimmune Uveitis Market
Autoimmune Uveitis Epidemiology Segmentation
The autoimmune uveitis epidemiology section provides insights into the historical and current autoimmune uveitis patient pool and forecasted trends for the leading markets. In 2025, NIU accounted for the highest proportion of diagnosed prevalent cases of uveitis in the US, with approximately 90% of cases, while infectious uveitis accounted for the least, with around 10% of cases.
The autoimmune uveitis treatment market report proffers epidemiological analysis for the study period 2022–2036 in the leading markets, segmented into:
Autoimmune Uveitis Market Report Metrics
Details
Study Period
2022–2036
Coverage
7MM [The United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Autoimmune Uveitis Market CAGR
7 %
Autoimmune Uveitis Market Size in 2025
USD 1.2 Billion
Key Autoimmune Uveitis Companies
Priovant Therapeutics, Tarsier Pharma, Chugai Pharmaceutical, Novaliq, PulseSight Therapeutics, AbbVie, Harrow, and others
Key Autoimmune Uveitis Therapies
Brepocitinib, TRS01, RAY121, NOV05, PST-606, HUMIRA, TRIESENCE, and others
Scope of the Autoimmune Uveitis Market Report
Download the report to understand the autoimmune uveitis treatment market @ Autoimmune Uveitis Drugs
Table of Contents
1
Autoimmune Uveitis Market Key Insights
2
Autoimmune Uveitis Market Report Introduction
3
Executive Summary
4
Key Events
5
Epidemiology and Market Forecast Methodology
6
Autoimmune Uveitis Market Overview at a Glance
6.1
Clinical Landscape Analysis (By Phase, Molecule Type, and RoA)
6.2
Market Share (%) Distribution of Autoimmune Uveitis By Therapies in the 7MM, in 2025
6.3
Market Share (%) Distribution of Autoimmune Uveitis By Therapies in the 7MM, in 2036
7
Disease Background and Overview of Autoimmune Uveitis
7.1
Introduction
7.2
Types
7.3
Symptoms
7.4
Causes
7.5
Pathophysiology
7.6
Diagnosis
7.7
Treatment
8
Epidemiology and Patient Population of Autoimmune Uveitis
8.1
Key Findings
8.2
Assumptions and Rationale
8.3
Total Prevalent Cases of Uveitis in the 7MM
8.4
The United States
8.4.1
Total Diagnosed Prevalent Cases of Uveitis in the United States
8.4.2
Type-specific Diagnosed Prevalent Cases of Uveitis in the United States
8.4.3
Diagnosed Prevalent of NIU by Anatomical Location in the United States
8.4.4
Diagnosed Prevalent Cases of Autoimmune Uveitis in the United States
8.4.5
Etiology-specific Diagnosed Prevalent Cases of Autoimmune Uveitis in the United States
8.4.6
Total Treated Cases of Autoimmune Uveitis in the United States
8.5
EU4 and the UK
8.6
Japan
9
Patient Journey of Autoimmune Uveitis
10
Marketed Autoimmune Uveitis Therapies
10.1
Marketed Competitive Landscape of Autoimmune Uveitis
10.2
Adalimumab (HUMIRA): AbbVie
10.2.1
Drug Description
10.2.2
Regulatory Milestones
10.2.3
Other Developmental Activities
10.2.4
Summary of Pivotal Trials
10.2.5
Clinical Development
10.2.5.1
Clinical Trial Information
10.2.6
Analyst Views
List to be continued in the report…
11
Emerging Autoimmune Uveitis Therapies
11.1
Emerging Competitive Landscape of Autoimmune Uveitis
11.2
TRS01: Tarsier Pharma
11.2.1
Drug Description
11.2.2
Other Developmental Activity
11.2.3
Clinical Development
11.2.3.1
Clinical Trials Information
11.2.4
Analyst Views
11.3
RAY121: Chugai Pharmaceutical
List to be continued in the report…
12
Autoimmune Uveitis Market: 7MM Analysis
12.1
Key Findings
12.2
Market Outlook of Autoimmune Uveitis
12.3
Key Autoimmune Uveitis Market Forecast Assumptions
12.4
Conjoint Analysis of Autoimmune Uveitis
12.5
Total Market Size of Autoimmune Uveitis in the 7MM
12.6
Total Market Size of Autoimmune Uveitis by Therapies in the 7MM
12.7
The United States Autoimmune Uveitis Market
12.7.1
Total Market Size of Autoimmune Uveitis in the United States
12.7.2
Total Market Size of Autoimmune Uveitis by Therapies in the United States
12.8
EU4 and the UK Autoimmune Uveitis Market
12.9
Japan Autoimmune Uveitis Market
13
Unmet Needs of Autoimmune Uveitis
14
SWOT Analysis of Autoimmune Uveitis
15
KOL Views of Autoimmune Uveitis
16
Market Access and Reimbursement
16.1
The United States
16.2
EU4 and the UK
16.3
Japan
16.4
Summary and comparison of Market Access and Pricing Policy Developments in 2025
16.5
Market Access and Reimbursement of Autoimmune Uveitis Therapies
17
Bibliography
18
Autoimmune Uveitis Market Report Methodology
Related Reports
Uveitis Market
Uveitis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key uveitis companies, including Tarsier Pharma, Oculis Pharma, Roche, Eleven Biotherapeutics, Eli Lilly and Company, Eyevensys, Acelyrin, Affibody Medical, Priovant Therapeutics, and others.
Uveitis Clinical Trial Analysis
Uveitis Pipeline – 2026 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key uveitis companies, including Eli Lilly and Company, VivaVision Biotech, Inc., Eyevensys, SFA Therapeutics, Tarsier Pharma, Chugai Pharmaceutical, and others.
Sarcoidosis Market
Sarcoidosis Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key sarcoidosis companies including Relief Therapeutics Holdings, aTyr Pharma, Amgen, Bristol-Myers Squibb, Novartis, Pfizer, United Therapeutics Corporation, and others.
Behçet's Disease Market
Behçet's Disease Market Insights, Epidemiology, and Market Forecast – 2036 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key Behçet's disease companies including AbbVie, Eisai Co. Ltd, Nobel Pharmaceuticals, Ainos Inc., Amgen, Ganzhou Hemay Pharmaceutical Co. Ltd, Janssen Korea Ltd, Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb, Hoffmann- La Roche, Novartis Pharmaceuticals, Abbott, Sanguine Biosciences, GlaxoSmithKline, IItoo Pharma, and others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
[email protected]
+14699457679
www.delveinsight.com
SOURCE DelveInsight Business Research, LLP